We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder (Exparox)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00540098
First Posted: October 5, 2007
Last Update Posted: October 5, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
GlaxoSmithKline
Information provided by:
University of Göttingen
  Purpose
Efficacy and safety of a 10-weeks treatment protocol of paroxetine vs. placebo in combination with regular aerobic exercise (running) or regular relaxation training in the treatment of panic disorder.

Condition Intervention Phase
Panic Disorder Drug: paroxetine + aerobic exercise Drug: Paroxetine + relaxation Drug: Placebo + aerobic exercise Drug: Placebo + relaxation Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled Trial on the Effects of Paroxetine Versus Placebo in Combination With Aerobic Exercise or Relaxation Training in the Treatment of Panic Disorder

Resource links provided by NLM:


Further study details as provided by University of Göttingen:

Primary Outcome Measures:
  • Severity of Panic disorder due to Scores on the Panic and Agoraphobia Scale (P&A) [ Time Frame: Baseline to endpoint (10 weeks) ]
  • Severity of panic disorder due to scores on the Clinical Global Impression scale (CGI) [ Time Frame: Baseline to endpoint (10 weeks) ]

Secondary Outcome Measures:
  • Symptom severity due to Hamilton Anxiety Scale (HAMA) [ Time Frame: Baseline to endpoint (10 weeks) ]
  • Symptom severity due to the Montgomery and Asberg depression rating scale (MADRS) [ Time Frame: Baseline to endpoint (10 weeks) ]
  • Response and remission analysis between groups [ Time Frame: LOCF-analysis ]

Enrollment: 75
Study Start Date: September 2001
Study Completion Date: June 2005
Arms Assigned Interventions
Experimental: 1
Paroxetine + aerobic exercise
Drug: paroxetine + aerobic exercise
paroxetine, 40 mg once daily + regular aerobic exercise
Active Comparator: 2
Paroxetine + relaxation
Drug: Paroxetine + relaxation
paroxetine, 40 mg once daily + regular relaxation training
Active Comparator: 3
Placebo + aerobic exercise
Drug: Placebo + aerobic exercise
placebo pill once daily + regular aerobic exercise
Placebo Comparator: 4
Placebo + relaxation
Drug: Placebo + relaxation
placebo pill once daily + regular relaxation training

Detailed Description:
In continuation of prior work from our group (Broocks A, Bandelow B, Pekrun G, et al. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry 1998; 155(5):603-9.) it is the purpose of this trial to test the assumed superiority of a combined therapy of paroxetine and aerobic exercise compared to placebo or unspecific relaxation training in panic disorder. Participants were randomized to a 10 week treatment protocol of paroxetine 40 mg daily or placebo in combination with regular exercise or regular relaxation after having given informed consent and screening of in- and exclusion criteria.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Panic disorder with or without agoraphobia due to DSM-IV
  • Written informed consent
  • Score of 17 or more on the P&A scale
  • Score on the CGI of 4 or more (markedly ill)

Exclusion Criteria:

  • Pregnancy, lactating or insufficient contraception (pearl index >1)
  • Other psychiatric disorders such as psychoses, addictive disorders, dementia, etc.
  • Clinically relevant abnormalities in physical examination or laboratory results
  • Prior major depression or bipolar disorder
  • Suicidality
  • psychotropic medication other than promethazine
  • current psychological treatment
  • unable to perform regular aerobic exercise
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00540098


Locations
Germany
University of Göttingen, Dept of Psychiatry and Psychotherapy
Göttingen, Germany, 37075
Sponsors and Collaborators
University of Göttingen
GlaxoSmithKline
Investigators
Principal Investigator: Borwin Bandelow, Prof, MD University of Göttingen
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00540098     History of Changes
Other Study ID Numbers: 290060/552
First Submitted: October 3, 2007
First Posted: October 5, 2007
Last Update Posted: October 5, 2007
Last Verified: October 2007

Keywords provided by University of Göttingen:
panic disorder
pharmacotherapy
non-pharmacological treatment
SSRI
paroxetine
exercise

Additional relevant MeSH terms:
Disease
Panic Disorder
Pathologic Processes
Anxiety Disorders
Mental Disorders
Paroxetine
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors